Cargando…

E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial

AIM: To examine whether, in adults receiving behavioral support, offering e-cigarettes together with varenicline helps more people stop smoking cigarettes than varenicline alone. METHODS: A two-group, parallel arm, pragmatic randomized controlled trial was conducted in six English stop smoking servi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tattan-Birch, Harry, Kock, Loren, Brown, Jamie, Beard, Emma, Bauld, Linda, West, Robert, Shahab, Lion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384384/
https://www.ncbi.nlm.nih.gov/pubmed/35738868
http://dx.doi.org/10.1093/ntr/ntac149
_version_ 1784769434829717504
author Tattan-Birch, Harry
Kock, Loren
Brown, Jamie
Beard, Emma
Bauld, Linda
West, Robert
Shahab, Lion
author_facet Tattan-Birch, Harry
Kock, Loren
Brown, Jamie
Beard, Emma
Bauld, Linda
West, Robert
Shahab, Lion
author_sort Tattan-Birch, Harry
collection PubMed
description AIM: To examine whether, in adults receiving behavioral support, offering e-cigarettes together with varenicline helps more people stop smoking cigarettes than varenicline alone. METHODS: A two-group, parallel arm, pragmatic randomized controlled trial was conducted in six English stop smoking services from 2019–2020. Adults enrolled onto a 12-week programme of in-person one-to-one behavioral smoking cessation support (N  =  92) were randomized to receive either (1) a nicotine e-cigarette starter kit alongside varenicline or (2) varenicline alone. The primary outcome was biochemically verified abstinence from cigarette smoking between weeks 9-to-12 post quit date, with those lost to follow-up considered not abstinent. The trial was stopped early due to COVID-19 restrictions and a varenicline recall (92/1266 participants used). RESULTS: Nine-to-12-week smoking abstinence rates were 47.9% (23/48) in the e-cigarette-varenicline group compared with 31.8% (14/44) in the varenicline-only group, a 51% increase in abstinence among those offered e-cigarettes; however, the confidence interval (CI) was wide, including the possibility of no difference (risk ratio [RR] = 1.51, 95% CI = 0.91–2.64). The e-cigarette-varenicline group had 43% lower hazards of relapse from continuous abstinence than the varenicline-only group (hazards ratio [HR] = 0.57, 95% CI =  0.34–0.96). Attendance for 12 weeks was higher in the e-cigarette-varenicline than varenicline-only group (54.2% vs. 36.4%; RR = 1.49, 95% CI = 0.95–2.47), but similar proportions of participants in both groups used varenicline daily for ≥8 weeks after quitting (22.9% versus 22.7%; RR = 1.01, 95% CI = 0.47–2.20). Estimates were too imprecise to determine how adverse events differed by group. CONCLUSION: Tentative evidence suggests that offering e-cigarettes alongside varenicline to people receiving behavioral support may be more effective for smoking cessation than varenicline alone. IMPLICATIONS: Offering e-cigarettes to people quitting smoking with varenicline may help them remain abstinent from cigarettes, but the evidence is tentative because our sample size was smaller than planned—caused by Coronavirus Disease 2019 (COVID-19) restrictions and a manufacturing recall. This meant our effect estimates were imprecise, and additional evidence is needed to confirm that providing e-cigarettes and varenicline together helps more people remain abstinent than varenicline alone.
format Online
Article
Text
id pubmed-9384384
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93843842022-08-18 E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial Tattan-Birch, Harry Kock, Loren Brown, Jamie Beard, Emma Bauld, Linda West, Robert Shahab, Lion Nicotine Tob Res Original Investigations AIM: To examine whether, in adults receiving behavioral support, offering e-cigarettes together with varenicline helps more people stop smoking cigarettes than varenicline alone. METHODS: A two-group, parallel arm, pragmatic randomized controlled trial was conducted in six English stop smoking services from 2019–2020. Adults enrolled onto a 12-week programme of in-person one-to-one behavioral smoking cessation support (N  =  92) were randomized to receive either (1) a nicotine e-cigarette starter kit alongside varenicline or (2) varenicline alone. The primary outcome was biochemically verified abstinence from cigarette smoking between weeks 9-to-12 post quit date, with those lost to follow-up considered not abstinent. The trial was stopped early due to COVID-19 restrictions and a varenicline recall (92/1266 participants used). RESULTS: Nine-to-12-week smoking abstinence rates were 47.9% (23/48) in the e-cigarette-varenicline group compared with 31.8% (14/44) in the varenicline-only group, a 51% increase in abstinence among those offered e-cigarettes; however, the confidence interval (CI) was wide, including the possibility of no difference (risk ratio [RR] = 1.51, 95% CI = 0.91–2.64). The e-cigarette-varenicline group had 43% lower hazards of relapse from continuous abstinence than the varenicline-only group (hazards ratio [HR] = 0.57, 95% CI =  0.34–0.96). Attendance for 12 weeks was higher in the e-cigarette-varenicline than varenicline-only group (54.2% vs. 36.4%; RR = 1.49, 95% CI = 0.95–2.47), but similar proportions of participants in both groups used varenicline daily for ≥8 weeks after quitting (22.9% versus 22.7%; RR = 1.01, 95% CI = 0.47–2.20). Estimates were too imprecise to determine how adverse events differed by group. CONCLUSION: Tentative evidence suggests that offering e-cigarettes alongside varenicline to people receiving behavioral support may be more effective for smoking cessation than varenicline alone. IMPLICATIONS: Offering e-cigarettes to people quitting smoking with varenicline may help them remain abstinent from cigarettes, but the evidence is tentative because our sample size was smaller than planned—caused by Coronavirus Disease 2019 (COVID-19) restrictions and a manufacturing recall. This meant our effect estimates were imprecise, and additional evidence is needed to confirm that providing e-cigarettes and varenicline together helps more people remain abstinent than varenicline alone. Oxford University Press 2022-06-23 /pmc/articles/PMC9384384/ /pubmed/35738868 http://dx.doi.org/10.1093/ntr/ntac149 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigations
Tattan-Birch, Harry
Kock, Loren
Brown, Jamie
Beard, Emma
Bauld, Linda
West, Robert
Shahab, Lion
E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial
title E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial
title_full E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial
title_fullStr E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial
title_full_unstemmed E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial
title_short E-cigarettes to Augment Stop Smoking In-person Support and Treatment With Varenicline (E-ASSIST): A Pragmatic Randomized Controlled Trial
title_sort e-cigarettes to augment stop smoking in-person support and treatment with varenicline (e-assist): a pragmatic randomized controlled trial
topic Original Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384384/
https://www.ncbi.nlm.nih.gov/pubmed/35738868
http://dx.doi.org/10.1093/ntr/ntac149
work_keys_str_mv AT tattanbirchharry ecigarettestoaugmentstopsmokinginpersonsupportandtreatmentwithvareniclineeassistapragmaticrandomizedcontrolledtrial
AT kockloren ecigarettestoaugmentstopsmokinginpersonsupportandtreatmentwithvareniclineeassistapragmaticrandomizedcontrolledtrial
AT brownjamie ecigarettestoaugmentstopsmokinginpersonsupportandtreatmentwithvareniclineeassistapragmaticrandomizedcontrolledtrial
AT beardemma ecigarettestoaugmentstopsmokinginpersonsupportandtreatmentwithvareniclineeassistapragmaticrandomizedcontrolledtrial
AT bauldlinda ecigarettestoaugmentstopsmokinginpersonsupportandtreatmentwithvareniclineeassistapragmaticrandomizedcontrolledtrial
AT westrobert ecigarettestoaugmentstopsmokinginpersonsupportandtreatmentwithvareniclineeassistapragmaticrandomizedcontrolledtrial
AT shahablion ecigarettestoaugmentstopsmokinginpersonsupportandtreatmentwithvareniclineeassistapragmaticrandomizedcontrolledtrial